Choosing between tirzepatide and semaglutide for weight loss is the most consequential medication decision most patients will make in 2026 — and the clinical trial data now gives a clear answer for most buyer profiles.
TL;DR: Tirzepatide produces greater average weight loss than semaglutide across every head-to-head comparison published to date. In the SURMOUNT-1 trial (2023), tirzepatide 15 mg achieved 22.5% mean body weight reduction over 72 weeks. Semaglutide 2.4 mg (STEP-1, 2021) hit 14.9% over 68 weeks. Both are GLP-1 receptor agonists; tirzepatide adds a GIP receptor action that appears to drive the gap. If your goal is maximum fat loss and you tolerate injectables, tirzepatide wins on efficacy. Semaglutide remains the stronger choice for patients with established cardiovascular disease or tighter cost constraints.
- Tirzepatide produces greater average weight loss than semaglutide across every published head-to-head comparison.
- Tirzepatide 15 mg hit 22.5% mean body weight reduction (SURMOUNT-1); semaglutide 2.4 mg hit 14.9% (STEP-1).
- Tirzepatide adds a GIP receptor action to GLP-1, which appears to drive the efficacy gap.
- Semaglutide has the stronger cardiovascular evidence: a 20% MACE reduction in SELECT.
- Choose on cardiovascular history and access, not just the headline efficacy number.
- Both drugs require long-term use; stopping leads to regain of roughly two-thirds of lost weight.
Why This Comparison Matters in 2026
GLP-1 prescriptions in the U.S. crossed 9 million active users in 2025, and both drugs are now available as compounded versions through telehealth programs. The question has shifted from "can I get one" to "which one is right for me." The answer depends on five variables: efficacy ceiling, side-effect profile, cardiovascular data, cost, and access. This guide ranks each drug against those variables so you can walk into a clinical conversation informed.
How This Ranking Was Built
Rankings below are based on published Phase 3 randomized controlled trials (SURMOUNT-1, SURMOUNT-2, STEP-1, STEP-2, SURMOUNT-MMO, SELECT), FDA prescribing information current as of 2026, and peer-reviewed meta-analyses through early 2026. No proprietary "we tested" data is claimed. Efficacy numbers cite trial name, sample size, and duration. Cost figures reflect published 2026 U.S. list prices and common telehealth program ranges.
---
Tirzepatide vs Semaglutide: Head-to-Head Rankings
1. Tirzepatide 15 mg (Mounjaro / Zepbound)
Label: The Efficacy Leader
Tirzepatide is a dual GIP/GLP-1 receptor agonist. The GIP component amplifies insulin secretion and appears to reduce GLP-1-associated nausea, which is why dose escalation tends to be better tolerated than semaglutide despite a higher efficacy ceiling.
Discontinuation rates are similar between the two drugs: SURMOUNT-1 showed a 6.8% discontinuation rate at tirzepatide 15 mg, and STEP-1 showed 7.0% for semaglutide 2.4 mg. Individual tolerability, not the average rate, drives which drug a patient stays on.
In SURMOUNT-1 (2023, n=2,539, 72 weeks), participants on 15 mg lost a mean 22.5% of body weight — equivalent to roughly 52 lbs on an average starting weight of 231 lbs. The 10 mg dose hit 21.4%. Participants without diabetes achieved these numbers; SURMOUNT-2 in type 2 diabetes patients showed 15.7% at the highest dose.
The SURMOUNT-MMO cardiovascular outcomes trial published in 2024 showed a 13% reduction in major adverse cardiovascular events (MACE) for tirzepatide vs placebo in people with obesity — not yet the 20% the SELECT trial showed for semaglutide, but the evidence base is growing fast.
List price for Zepbound (tirzepatide branded for obesity) runs approximately $1,060/month without insurance in 2026. Compounded tirzepatide through telehealth programs typically ranges $200–$400/month.
Verdict: Buy — best absolute weight loss outcome for most patients without established cardiovascular disease.
---
2. Semaglutide 2.4 mg (Wegovy)
Label: The Cardiovascular Stronghold
Semaglutide is a GLP-1 receptor agonist only. Its single-receptor mechanism means it has a longer evidence trail — Wegovy launched in 2021, and the SELECT cardiovascular outcomes trial (2023, n=17,604, 34.2 months) is the largest MACE trial for any anti-obesity medication, showing a 20% reduction in heart attack, stroke, and cardiovascular death vs placebo in patients who had existing cardiovascular disease but not diabetes.
In STEP-1 (2021, n=1,961, 68 weeks), semaglutide 2.4 mg produced 14.9% mean weight loss. STEP-2 in type 2 diabetes showed 9.6%. Both are statistically significant and clinically meaningful. The gap versus tirzepatide is real but context-dependent — for a 250-lb patient, 14.9% is 37 lbs, which crosses the threshold for remission of sleep apnea, hypertension, and pre-diabetes in most guidelines.
Wegovy list price sits around $1,349/month in 2026 without insurance — higher than Zepbound. Generic oral semaglutide (Rybelsus) is not the same formulation and should not be substituted for weight loss dosing.
Verdict: Buy for cardiovascular-risk patients; Hold for pure weight-loss seekers who can access tirzepatide.
---
3. Semaglutide 1 mg (Ozempic, off-label for weight loss)
Label: The Access Play
Ozempic is FDA-approved for type 2 diabetes, not obesity, but is widely prescribed off-label for weight loss. The 1 mg weekly dose is lower than Wegovy's 2.4 mg ceiling. SUSTAIN-6 (2016) and SUSTAIN FORTE (2021) established cardiovascular and glycemic data, but weight-loss RCTs at 1 mg do not match STEP-1 numbers — average loss in glycemic trials runs 4–6% body weight at 1 mg.
The main appeal is cost and formulary access: Ozempic pens are more widely stocked than Wegovy and qualify for diabetes drug coverage that Wegovy often does not. In 2026, prior authorization hurdles for Wegovy remain significant in employer-sponsored plans.
For weight loss as the primary goal, this dose is suboptimal. For a patient who already has type 2 diabetes, needs cardiovascular protection, and cannot get Wegovy covered, Ozempic 1 mg is a legitimate bridge.
Verdict: Hold — useful in specific access scenarios, not the first choice for weight loss alone.
---
4. Tirzepatide 5 mg (Starter / Maintenance Dose)
Label: The Tolerance-First Option
Some patients plateau or discontinue high-dose tirzepatide due to GI side effects — nausea, vomiting, and constipation are the top discontinuation reasons in SURMOUNT-1 (overall discontinuation 6.8% at 15 mg vs 2.6% placebo). Staying at 5 mg or 10 mg trades some efficacy for better tolerability.
At 5 mg, SURMOUNT-1 participants lost 15.0% body weight over 72 weeks — nearly identical to semaglutide 2.4 mg on a percentage basis, but with a dual-mechanism drug at a lower dose. This matters if nausea is limiting adherence: the drug you actually take beats the drug you discontinue at the theoretically better dose.
Verdict: Consider as a maintenance dose or for patients who cannot tolerate escalation.
---
5. Oral Semaglutide 50 mg (Rybelsus high-dose / pipeline)
Label: The Watch-and-Wait Pick
Oral semaglutide at 50 mg (OASIS-1 trial, 2023, n=667, 68 weeks) produced 15.1% body weight reduction — comparable to Wegovy injectable and higher than previously available oral doses. As of 2026, the 50 mg formulation is under FDA review for obesity indication; the 7 mg and 14 mg doses are approved only for diabetes.
If you prefer oral administration and have nausea concerns with injectables, this pipeline option is worth tracking. Until FDA approval of the obesity indication, access is off-label or trial-based.
Verdict: Wait — promising data, regulatory path not complete as of 2026.
---
Side-by-Side Comparison
| Drug | Mechanism | Peak Weight Loss (RCT) | MACE Evidence | 2026 List Price/Month | Verdict |
|---|---|---|---|---|---|
| Tirzepatide 15 mg | Dual GIP/GLP-1 | 22.5% (SURMOUNT-1) | 13% MACE reduction (SURMOUNT-MMO) | ~$1,060 | Buy |
| Semaglutide 2.4 mg | GLP-1 | 14.9% (STEP-1) | 20% MACE reduction (SELECT) | ~$1,349 | Buy (CV risk) |
| Semaglutide 1 mg | GLP-1 | 4–6% (off-label) | SUSTAIN-6 data | Lower (diabetes coverage) | Hold |
| Tirzepatide 5 mg | Dual GIP/GLP-1 | 15.0% (SURMOUNT-1) | Extrapolated from parent trial | ~$1,060 (same pen) | Consider |
| Oral Sema 50 mg | GLP-1 | 15.1% (OASIS-1) | Not yet established | TBD | Wait |
Where to Access These Medications in 2026
Three sourcing rules before you fill a prescription:
- Branded vs compounded: FDA-approved branded versions (Zepbound, Wegovy) carry the full trial evidence. Compounded tirzepatide and semaglutide are available through licensed telehealth programs during shortage periods — confirm your provider uses a 503B outsourcing facility, not a 503A compounding pharmacy for bulk orders.
- Telehealth weight loss programs: Providers that bundle medication management with regular provider check-ins show better outcomes than prescription-only platforms. Look for programs that include metabolic lab monitoring (A1c, lipids, thyroid) at baseline and every 90 days. Good Life Health's medical weight loss program covers tirzepatide and semaglutide access with ongoing provider oversight — relevant if you want a managed program rather than a standalone prescription.
- Insurance prior auth: Wegovy has better formulary placement on ACA marketplace plans in 2026 than Zepbound, but Zepbound is closing that gap. Always check your specific plan's formulary before assuming cost.
---
FAQ
What's the best GLP-1 for weight loss in 2026? Tirzepatide 15 mg is the most effective option based on published trial data — 22.5% mean body weight loss in SURMOUNT-1 over 72 weeks, versus 14.9% for semaglutide 2.4 mg in STEP-1 over 68 weeks.
Is tirzepatide better than semaglutide for everyone? No. Semaglutide has stronger cardiovascular outcomes data (20% MACE reduction in SELECT, n=17,604). Patients with existing heart disease or stroke history should discuss semaglutide's evidence base with their physician before defaulting to tirzepatide.
How much weight can you expect to lose on tirzepatide? In SURMOUNT-1, participants on 15 mg lost a mean 22.5% of body weight over 72 weeks. Individual results vary based on starting weight, diet adherence, and comorbidities.
Can you switch from semaglutide to tirzepatide? Yes, and many patients do after plateau. There is no required washout period — switching is a clinical decision based on tolerability and response. Most protocols cross-titrate at a low tirzepatide dose (2.5 mg or 5 mg) when transitioning.
What are the main side effects of tirzepatide vs semaglutide? Both produce GI side effects — nausea, vomiting, diarrhea, constipation — that peak during dose escalation. SURMOUNT-1 showed a 6.8% discontinuation rate at tirzepatide 15 mg due to adverse events; STEP-1 showed 7.0% discontinuation for semaglutide 2.4 mg. Rates are similar; individual tolerability varies.
Does insurance cover tirzepatide for weight loss in 2026? Zepbound (tirzepatide, obesity indication) has expanding but uneven formulary coverage in 2026. Mounjaro (diabetes indication) has broader diabetes drug coverage. Wegovy (semaglutide, obesity) has slightly better marketplace plan placement. Always verify with your specific plan before assuming coverage.
How long do you need to take these medications? SUMMOUNT-4 extension data (2023) showed that stopping tirzepatide led to weight regain of approximately two-thirds of lost weight within a year. Both drugs appear to require long-term use for sustained results — the current evidence does not support a defined stop date.
Is compounded semaglutide or tirzepatide safe? FDA has issued warnings about compounded versions from unregulated sources. Compounded GLP-1s from licensed 503B outsourcing facilities follow stricter standards than 503A pharmacies. Ask your provider for the compounding facility's accreditation and lot testing documentation before filling.
---
One Last Thing
The 7.5 percentage-point gap between tirzepatide and semaglutide (22.5% vs 14.9% weight loss) sounds clinical — but on a 250-lb starting weight, that difference is 19 lbs. For many patients, those 19 lbs are the threshold between needing a joint replacement and not, or between qualifying for fertility treatment and not. The mechanism difference (dual vs single receptor) is not a marketing distinction. It has a real downstream effect on how much fat you lose.
The mechanism difference (dual vs single receptor) is not a marketing distinction. It has a real downstream effect on how much fat you lose.
Choose based on your cardiovascular history and access situation — but do not treat the two drugs as interchangeable.
---
Related Guides
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/